Wall Street Thinks This Weight-Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.There's no secret to their success: Both companies have blockbuster weight-loss drugs. But the obesity market could soon have a new contender. Wall Street thinks this weight-loss drug stock could more than 3x over the next 12 months -- and it's not Eli Lilly or Novo Nordisk.Viking Therapeutics' (NASDAQ: VKTX) share price currently hovers around $32. The average analysts' 12-month price target for the biotech stock is $99.29 -- more than 200% higher.Continue reading
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as the largest drugmaker in the world, with a market cap of $844 billion, after its shares skyrocketed more than 270%. Novo Nordisk stock is up around 75% despite a pullback in recent months.
There's no secret to their success: Both companies have blockbuster weight-loss drugs. But the obesity market could soon have a new contender. Wall Street thinks this weight-loss drug stock could more than 3x over the next 12 months -- and it's not Eli Lilly or Novo Nordisk.
Viking Therapeutics' (NASDAQ: VKTX) share price currently hovers around $32. The average analysts' 12-month price target for the biotech stock is $99.29 -- more than 200% higher.
